A citation-based method for searching scientific literature

Ajay Varanasi, Natalie Bellini, Deepti Rawal, Mehul Vora, Antoine Makdissi, Sandeep Dhindsa, Ajay Chaudhuri, Paresh Dandona. Eur J Endocrinol 2011
Times Cited: 97







List of shared articles



Times cited

Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs Under Development.
Friedrich Mittermayer, Erica Caveney, Claudia De Oliveira, G Alexander Fleming, Loukas Gourgiotis, Mala Puri, Li-Jung Tai, J Rick Turner. Curr Diabetes Rev 2017
7

Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus.
Christian Seerup Frandsen, Thomas Fremming Dejgaard, Sten Madsbad. Lancet Diabetes Endocrinol 2016
45

GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach.
Isabella Crisci, Michele Aragona, Konstantina Savvina Politi, Giuseppe Daniele, Stefano Del Prato. Acta Diabetol 2015
10

Persistent C-peptide: what does it mean?
Massimo Pietropaolo. Curr Opin Endocrinol Diabetes Obes 2013
7

Liraglutide for treating type 1 diabetes.
Thomas Fremming Dejgaard, Christian Seerup Frandsen, Jens Juul Holst, Sten Madsbad. Expert Opin Biol Ther 2016
8

GLP-1 Agonists in Type 1 Diabetes Mellitus.
Kristin M Janzen, Taylor D Steuber, Sarah A Nisly. Ann Pharmacother 2016
15


Nutrient induced type 2 and chemical induced type 1 experimental diabetes differently modulate gastric GLP-1 receptor expression.
Olga Bloch, Efrat Broide, Gilad Ben-Yehudah, Dror Cantrell, Haim Shirin, Micha J Rapoport. J Diabetes Res 2015
4

Non-insulin pharmacological therapies for treating type 1 diabetes.
Christian Seerup Frandsen, Thomas Fremming Dejgaard, Sten Madsbad, Jens Juul Holst. Expert Opin Pharmacother 2018
4



The potential of incretin-based therapies in type 1 diabetes.
Chen S Suen, Paul Burn. Drug Discov Today 2012
19

Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm.
Venkat Sasidhar Renukuntla, Neesha Ramchandani, Jeniece Trast, Martin Cantwell, Rubina A Heptulla. J Diabetes Sci Technol 2014
26

Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
Thomas Fremming Dejgaard, Christian Seerup Frandsen, Tanja Stenbæk Hansen, Thomas Almdal, Søren Urhammer, Ulrik Pedersen-Bjergaard, Tonny Jensen, Andreas Kryger Jensen, Jens Juul Holst, Lise Tarnow,[...]. Lancet Diabetes Endocrinol 2016
67



Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study.
Thomas Fremming Dejgaard, Filip Krag Knop, Lise Tarnow, Christian Seerup Frandsen, Tanja Stenbæk Hansen, Thomas Almdal, Jens Juul Holst, Sten Madsbad, Henrik Ullits Andersen. BMJ Open 2015
9



Recent advances in incretin-based therapies.
David Russell-Jones, Stephen Gough. Clin Endocrinol (Oxf) 2012
49

Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.
Bo Ahrén, Irl B Hirsch, Thomas R Pieber, Chantal Mathieu, Fernando Gómez-Peralta, Troels Krarup Hansen, Areti Philotheou, Sune Birch, Erik Christiansen, Thomas Jon Jensen,[...]. Diabetes Care 2016
68


Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study.
Christian S Frandsen, Thomas F Dejgaard, Jens J Holst, Henrik U Andersen, Birger Thorsteinsson, Sten Madsbad. Diabetes Care 2015
50